Metabolic and Endocrine Therapeutics
Tecnimede-Sociedade Tecnico-Medicinal S.A. has active clinical research in type 2 diabetes-related treatment areas, with work centered on empagliflozin, canagliflozin, and alogliptin formulations. This includes interest in SGLT2 inhibitors and DPP-4 inhibitors used in glycaemic management.
- Empagliflozin
- Canagliflozin
- Alogliptin
- SGLT2 inhibitor
- DPP-4 inhibitor
The sponsor also investigates combination-related therapeutic areas involving glucose-lowering agents, reflecting a focus on oral treatments for metabolic disease.
Bioequivalence and Comparative Pharmacokinetics
Several studies are directed toward bioequivalence and comparative bioavailability of film-coated tablets, indicating a strong interest in the therapeutic interchangeability of branded and test products. The research includes oral formulations of linagliptin and teriflunomide alongside diabetes medicines.
- Bioequivalence
- Comparative bioavailability
- Film-coated tablets
- Linagliptin
- Teriflunomide
These activities show a therapeutic emphasis on establishing comparable exposure profiles for orally administered medicines across multiple active ingredients.
Neurology and Autoimmune Medicine
The inclusion of teriflunomide points to research interest in multiple sclerosis and related autoimmune disease treatment. This expands the sponsor’s clinical portfolio beyond metabolic care into neurological and immune-mediated therapeutic domains.
- Teriflunomide
- Multiple sclerosis
- Autoimmune disease
Work in this area is focused on oral therapies used in chronic conditions requiring long-term disease control.
Healthy Volunteer Pharmacology
The sponsor’s studies are conducted in healthy participants and center on fasting conditions, supporting research in human pharmacology for oral medicines. This includes evaluation of how individual products behave when administered alone or in combination.
- Healthy participants
- Fasting conditions
- Oral medicine
- Drug-drug interaction
Within this area, the sponsor’s work spans both single-agent assessment and interaction-focused studies for marketed therapeutic classes.
